The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Peptide ELISA: Antibody detection limit dilution 1/128000.
WB: Use at a concentration of 0.1 - 0.3 µg/ml. Detects a band of approximately 58 kDa (predicted molecular weight: 58 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Brain, placenta and gonads.
Defects in CYP19A1 are a cause of aromatase excess syndrome (AEXS) [MIM:139300]; also known as familial gynecomastia. AEXS is characterized by an estrogen excess due to an increased aromatase activity. Defects in CYP19A1 are the cause of aromatase deficiency (AROD) [MIM:107910]. AROD is a rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries.